WO2004001422A3 - Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases - Google Patents

Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases Download PDF

Info

Publication number
WO2004001422A3
WO2004001422A3 PCT/EP2003/006521 EP0306521W WO2004001422A3 WO 2004001422 A3 WO2004001422 A3 WO 2004001422A3 EP 0306521 W EP0306521 W EP 0306521W WO 2004001422 A3 WO2004001422 A3 WO 2004001422A3
Authority
WO
WIPO (PCT)
Prior art keywords
g3bp2
disease
gtpase
ras
diagnostic
Prior art date
Application number
PCT/EP2003/006521
Other languages
French (fr)
Other versions
WO2004001422A2 (en
Inventor
Der Kammer Heinz Von
Johannes Pohlner
Original Assignee
Evotec Neurosciences Gmbh
Der Kammer Heinz Von
Johannes Pohlner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Neurosciences Gmbh, Der Kammer Heinz Von, Johannes Pohlner filed Critical Evotec Neurosciences Gmbh
Priority to AU2003278497A priority Critical patent/AU2003278497A1/en
Priority to EP03740295A priority patent/EP1514118A2/en
Publication of WO2004001422A2 publication Critical patent/WO2004001422A2/en
Publication of WO2004001422A3 publication Critical patent/WO2004001422A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention discloses the differential expression of the G3BP2 gene in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk of developing such a disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the G3BP2 gene and its corresponding gene products. A method of screening for modulating agents of neuro-degenerative diseases is also disclosed.
PCT/EP2003/006521 2002-06-20 2003-06-20 Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases WO2004001422A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003278497A AU2003278497A1 (en) 2002-06-20 2003-06-20 Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
EP03740295A EP1514118A2 (en) 2002-06-20 2003-06-20 Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38992702P 2002-06-20 2002-06-20
US60/389,927 2002-06-20
EP02013692 2002-06-20
EP02013692.5 2002-06-20

Publications (2)

Publication Number Publication Date
WO2004001422A2 WO2004001422A2 (en) 2003-12-31
WO2004001422A3 true WO2004001422A3 (en) 2004-03-18

Family

ID=56290442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/006521 WO2004001422A2 (en) 2002-06-20 2003-06-20 Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases

Country Status (3)

Country Link
EP (1) EP1514118A2 (en)
AU (1) AU2003278497A1 (en)
WO (1) WO2004001422A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2419332A (en) 2004-10-22 2006-04-26 Gibbs Tech Ltd Steering arrangement with retractable wheels
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2023174838A1 (en) * 2022-03-14 2023-09-21 F. Hoffmann-La Roche Ag Modulators of the g3bp2-tau interaction for the treatment of tau associated diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780062A1 (en) * 1998-06-17 1999-12-24 Rhone Poulenc Rorer Sa MONOCLONAL ANTIBODIES DIRECTED AGAINST THE PROTEIN G3BP, AND USES THEREOF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780062A1 (en) * 1998-06-17 1999-12-24 Rhone Poulenc Rorer Sa MONOCLONAL ANTIBODIES DIRECTED AGAINST THE PROTEIN G3BP, AND USES THEREOF

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BARDONI BARBARA ET AL: "Advances in understanding of fragile X pathogenesis and FMRP function, and in identification of X linked mental retardation genes.", CURRENT OPINION IN GENETICS & DEVELOPMENT, vol. 12, no. 3, June 2002 (2002-06-01), pages 284 - 293, XP002226587, ISSN: 0959-437X *
KENNEDY DEREK ET AL: "Characterization of G3BPs: Tissue specific expression, chromosomal localisation and rasGAP120 binding studies.", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 84, no. 1, 2001, pages 173 - 187, XP002226585, ISSN: 0730-2312 *
PRIGENT MAGALI ET AL: "IkappaBalpha and IkappaBalpha/NF-kappaB complexes are retained in the cytoplasm through interaction with a novel partner, RasGAP SH3-binding protein 2.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 46, 2000, pages 36441 - 36449, XP002226586, ISSN: 0021-9258 *
See also references of EP1514118A2 *
ZHONG N ET AL: "REDUCED MRNA FOR G3BP IN FRAGILE X CELLS: EVIDENCE OF FMR1 GENE REGULATION", AMERICAN JOURNAL OF MEDICAL GENETICS, NEW YORK,NY, US, vol. 84, no. 3, 28 May 1999 (1999-05-28), pages 268 - 271, XP001132017 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9176150B2 (en) 2003-01-31 2015-11-03 AbbVie Deutschland GmbH & Co. KG Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US8497072B2 (en) 2005-11-30 2013-07-30 Abbott Laboratories Amyloid-beta globulomer antibodies
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
US9540432B2 (en) 2005-11-30 2017-01-10 AbbVie Deutschland GmbH & Co. KG Anti-Aβ globulomer 7C6 antibodies
US8877190B2 (en) 2006-11-30 2014-11-04 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9359430B2 (en) 2006-11-30 2016-06-07 Abbvie Inc. Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
US9394360B2 (en) 2006-11-30 2016-07-19 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
AU2003278497A1 (en) 2004-01-06
WO2004001422A2 (en) 2003-12-31
EP1514118A2 (en) 2005-03-16
AU2003278497A8 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
WO2005108999A3 (en) Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease
WO2006125830A3 (en) Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases
WO2004065576A3 (en) Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
WO2004070388A8 (en) Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
WO2004043226A3 (en) Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease
WO2004003563A3 (en) Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
WO2002016636A3 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
WO2004038411A3 (en) Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases
AU2003224120A1 (en) Diagnostic and therapeutic use of ensadin-0477 gene and protein for neurodegenerative diseases
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
WO2006134128A3 (en) Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases
WO2005030947A3 (en) Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases
WO2003087403A3 (en) Diagnostic and therapeutic use of a golgi protein for neurodegenerative diseases
WO2005085472A3 (en) Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
WO2005059562A3 (en) Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases
WO2003100092A3 (en) Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases
DE60235996D1 (en) DIAGNOSTIC AND THERAPEUTIC USE OF F-BOX PROTEINS IN MORBUS ALZHEIMER AND RELATED NEURODEGENERATIVE ILLNESSES
WO2004035823A3 (en) Diagnostic and therapeutic use of the nicotinamide mononucleotide adenylytransferase 2 (nmnat-2) gene and protein for neurodegenerative diseases
WO2003069347A3 (en) Diagnostic and therapeutic use of caps
WO2003104811A3 (en) Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases
WO2003085131A3 (en) Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases
WO2005101014A3 (en) Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases
WO2004020665A3 (en) Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases
WO2005071418A3 (en) Diagnostic and therapeutic use of the human dax- 1 gene and protein for neurodegenerative diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003740295

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003740295

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP